&w=3840&q=100)
Tricog, Omron eye 100 mn patient screenings for cardiac health by 2030
KeeboHealth is a digital health ecosystem that harnesses advanced AI, real-time data analytics, and home-based monitoring to empower both healthcare providers and patients in the effective management of heart conditions.
Moreover, the platform integrates with Omron's connected devices, such as home ECG monitors, blood pressure monitors, and weighing scales, to deliver personalised care.
Charit Bhograj, CEO and founder of Tricog Health, stated that approximately 3 million Indians die each year due to cardiovascular complications. The company highlighted that its goal is to reduce the mortality rate by 33 per cent through KeeboHealth.
'KeeboHealth is more than technology – it's hope for millions living with heart failure. By continuously analysing patient data and detecting early warning signs, we can deliver timely, tailored interventions, even in regions where access to specialists is limited,' Bhograj added.
Tricog told Business Standard that it has raised about $25 million as part of expansion and enhancing its in-house AI-capabilities, over ten years.
Further, Tricog has partnered with six Indian state governments such as Goa, Maharashtra, Telangana, Bihar, Karnataka and, to expand its AI-system for heart care. On the international front, Tricog also has a presence in the international markets serving South East Asia and East Africa.
Commenting on cardiac care, Bhograj highlighted that blood pressure remains a major contributing factor to heart-related issues. He said that the blood pressure monitoring market in the country is substantial, with an estimated 250 million people seeking access. Omron is one of the suppliers of BP monitors in India, along with nebulisers, thermometers, body composition monitors, and TENS (nerve stimulators).
Further, addressing the ongoing debate about COVID vaccines potentially causing heart attacks, Bhograj dismissed it, saying: 'No vaccines can cause heart attacks. There might be cases where they can cause allergies. Vaccines are safe. However, COVID has led to the weakening of our immune systems and can lead to heart complications.'
Omron has a strong footprint in 130 countries. In India, the device maker recorded a sales growth of 3–4 per cent in financial year 2024 (FY24). Omron opened its manufacturing facility in Chennai, Tamil Nadu, in March 2025. On the global front, China contributes about 30 per cent of its overall sales, marking a significantly large market.
While an exact price point has not been disclosed, Tricog has indicated that the product will be positioned within the affordable segment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
44 minutes ago
- Time of India
Cohance Lifesciences announces $10 million investment in US-based arm
Cohance Lifesciences on Tuesday announced a strategic investment of USD 10 million (around Rs 87.6 crore) to expand bioconjugation capabilities at its US-based subsidiary, NJ Bio . The investment advances Cohance's global expansion in niche technology-led modalities, enhancing its ability to support innovators from early development through late-phase clinical supply, the company said in a statement. Finance Value and Valuation Masterclass - Batch 4 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Finance Value and Valuation Masterclass - Batch 3 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals By Vaibhav Sisinity View Program Finance Value and Valuation Masterclass - Batch 2 By CA Himanshu Jain View Program Finance Value and Valuation Masterclass Batch-1 By CA Himanshu Jain View Program The common good manufacturing practices (cGMP) compliant bioconjugation suite at NJ Bio's Princeton, New Jersey, facility significantly strengthens the company's capabilities to deliver fully integrated Antibody-Drug Conjugate (ADC) solutions, it added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Top 32 Most Beautiful Women In The World Undo "The investment ... strengthening our footprint in the rapidly growing ADC space. By integrating payload-linker development and bioconjugation capabilities under one roof, NJ Bio will be well-positioned to support accelerated development timelines and help bring life-saving therapies to patients faster," Vivek Sharma, Executive Chairman, Cohance Lifesciences, said. In a separate statement, Cohance announced a Rs 23 crore investment and significant progress on its new oligonucleotide building block manufacturing facility in Hyderabad . Live Events "Together, these investments form part of Cohance's planned capacity expansion program across high-growth modalities, enhancing its ability to serve global innovators from early development to commercial supply," the company said. Cohance Lifesciences, formerly Suven Pharmaceuticals , is an innovator-focused global Contract Research, Development, and Manufacturing Organization (CRDMO), formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals.
News18
an hour ago
- News18
Manipal Hospitals to set up Rs 700 cr 350-bed facility in Nagpur
New Delhi, Aug 13 (PTI) Manipal Health Enterprises on Wednesday said it has inked a MoU with Maharastra government to set up a 350-bed multi-speciality Hospital at Nagpur entailing an investment of Rs 700 crore. The hospital is expected to commence operations in 2029 and generate about 3,000 new jobs. The Maharashtra government has promised to facilitate all permits, approvals and fiscal incentives necessary to complete this project in a time bound manner, the Bengaluru-based firm said in a statement. 'This strategic expansion aligns with Manipal Hospitals' vision to make advanced medical care accessible to all," Manipal Hospitals MD and CEO Dilip Jose said. view comments First Published: August 13, 2025, 16:45 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Hindustan Times
an hour ago
- Hindustan Times
Getting the organ donation policy right
In the last decade, India has made bold strides in health care, strengthening health systems, reducing maternal and child mortality, combating non-communicable diseases, and advancing universal access to quality health care. Yet when it comes to organ transplantation, unfortunately, a silent crisis continues to claim thousands of lives. Organ Donation Day is a reminder for us to take action to urgently address the need for organ donation on a larger scale. There is no greater tragedy than a life that is lost for want of an organ transplant. Nearly half a million Indians die every year waiting for a life-saving transplant due to the unavailability of organs. Losing a fellow Indian due to the lack of an organ for transplant is a preventable fatality we cannot accept. We have the medical expertise, and what we need now is a collective will at a national level to bridge the gap between organ supply and demand. The gap between patients' needs and organ availability and transplantation in India shows the need for urgent change. Around 200,000 patients with end-stage kidney disease, 50,000 patients with severe liver failure, and 50,000 patients with severe heart disease require a transplant to save their lives. Against this, only around 1,600 kidneys, 700 livers, and 300 hearts are transplanted each year. Every day, at least 15 patients die waiting for an organ. Every 10 minutes, a new name is added to the transplant waiting list, each life hanging in the balance. Fewer than 5% of patients with end-stage kidney disease receive a life-saving kidney transplant. The situation for heart and lung patients is even more dire. Despite our world-class transplant surgeons, India's organ donation rate remains among the lowest in the world — only 0.65 donors per million population. By contrast, countries like Spain and Croatia have donation rates of over 30 per million. This disparity shows that the shortage of organs in India is not just a medical limitation but also a societal and policy challenge. Organ donation is not just a clinical procedure — it is the ultimate act of humanity. One donor can save up to eight lives by donating their heart, lungs, liver, kidneys, pancreas, and tissues. To donate one's organs so that others may live is perhaps the noblest legacy one can leave. The story of Sanjay Kandasamy is a reminder of what is possible. In 1998, as a 20-month-old infant with end-stage liver failure, he underwent a liver transplant at Indraprastha Apollo Hospitals. His father donated a portion of his liver. Today, Sanjay is a practicing doctor saving lives. This is not just a story of science but is a story of second chances, of renewal, and of life itself. A persistent challenge is that families often refuse to give consent for organ donation, even when it aligns with the donor's own wishes. This has to change with awareness campaigns and policy changes. It is critical to have compassionate communication with the potential donor's family to reduce the refusal rate for organ donation. One bold policy step would be adopting a 'presumed consent' system for organ donation, as countries such as Singapore, Croatia, Spain, and others in Europe have done. Under 'presumed consent', every adult is presumed to be an organ donor after death, irrespective of their relatives' decision, unless they have explicitly registered their decision not to be. In Europe, the presumed consent policy has been found to have a positive impact on donation rates, with an increase in organ donations and willingness to donate organs. India has always led with bold ideas. The time has come when we must no longer allow our people to die for want of an organ. The gift of life must become a national priority, and with the right collective action, we can step into a future where every Indian who needs a transplant has a real chance to receive one. Prathap C Reddy is founder-chairman, Apollo Hospitals Group. The views expressed are personal.
